Bulletin from the Extraordinary General Meeting on 21st of October in Clinical Laserthermia Systems AB

Today, October 21, 2024, an Extraordinary General Meeting was held in Clinical Laserthermia Systems AB, org. no. 556705–8903. Below is a summary of the decisions taken.

Election of the Board of Directors (Item 6)

The general meeting resolved to re-elect Lars-Erik Eriksson, Marika Crohns, and Sandra Brandmeier as board members. Furthermore, the general meeting elected Peter Mantas and Peter Max as board members.

The newly appointed board elected Peter Max to be the chairman of the board immediately after the general meeting.

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com

Website: www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold directly or through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

Mer information om CLS finns på företagets webbplats: www.clinicallaser.se